Pharmaceutical powerhouse, Johnson & Johnson, has recently been the subject of several legal problems regarding the marketing practices for some of their most popular medications. The latest development involves the company’s Scios unit agreeing to pay an $85 million fine and plead guilty to misbranding the heart drug, Natrecor. In July, prosecutors charged Scios with [...]
